OTC Drug Market Opportunities In China

31 October 1994

With a population of 1.2 billion people, many of whom have amassed large savings and who enjoy a relatively high proportion of disposable income, China offers a major opportunity for marketers of consumer products. This opportunity is being opened up by a government intent on establishing a "socialist-capitalist" economy, which has actively encouraged the formation of hundreds of joint ventures between western and Chinese pharmaceutical companies, comments Nicholas Hall & Co, discussing its new report entitled China: OTC Entry Strategies to 2000.

Some of these companies, it says, have already introduced consumer brands known in developed markets, and these products are being advertised alongside other pharmaceuticals on Chinese national and regional television, as well as on satellite and cable stations. With TV audience penetration reaching 99% in some cities, relatively in-expensive advertising campaigns have already been seen by huge audiences and are promoting rapid growth rates for some brands.

Based on the effects of high-profile advertising and promotion, as well as a government commitment to the expansion of the market, sales of western-style pharmaceuticals reached around $2.3 billion in 1993, having grown ahead of inflation for many years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight